CAMBRIDGE, UK, 23 October 2023 – Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the publication of its peer-reviewed study in Xenobiotica, ‘Predicting routes of phase I and II metabolism based on quantum mechanics and machine learning’. In the paper, the team demonstrate a new method that better determines the routes of metabolism and metabolites in early drug discovery.
Unexpected metabolism can lead to late-stage drug candidate failure, or even the withdrawal of approved drugs. Early in silico prediction of the dominant routes of metabolism is therefore vital to improve a drug’s chance of success.
The paper first describes the development and validation of Optibrium’s WhichEnzyme™ model, which accurately predicts the enzyme families most likely to metabolise a drug candidate. The team then combine this new model with Optibrium’s previously published models. These include regioselectivity models for key Phase I and Phase II drug metabolising enzymes, which use quantum mechanical simulations with machine learning methods to predict sites of metabolism and the resulting metabolites. Additionally, the WhichP450 model, which predicts the Cytochrome P450 isoform(s) responsible for a compound’s metabolism.
Based on the combined model outputs, Optibrium showcase a new method to determine the most likely routes of metabolism and metabolites to be observed experimentally. The paper demonstrates that this method delivers high sensitivity in identifying experimentally reported metabolites, as well as higher precision than other methods for predicting in vivo metabolite profiles. It enables researchers to identify compounds with greater metabolic stability and better safety profiles, and underpins Optibrium’s recently launched StarDrop Metabolism module.
Our latest study is the result of six years of focused research, delivering a practical model that allows users to predict metabolic pathways for a wide range of drug-like compounds. Thanks to our carefully curated datasets and our signature reactivity-accessibility approach, we have managed to build accurate isoform-specific regioselectivity models for the important Phase I and II enzyme families,” Dr Mario Öeren, Principal Scientist, Optibrium, said. “Using that very same data, we’ve trained models that predict the likely enzyme families and isoforms which metabolise a compound. And then by combining these models, we’ve trained and validated a ‘model of models’ that predicts the full metabolism pathway for a given compound.”
Related content from across the site
7th RSC-BMCS AI in chemistry conference
The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
26th North American ISSX and JSSX Meeting
The joint ISSX/JSSX meeting is for researchers looking to gain a deeper understanding of drug metabolism and pharmacokinetics.
Optibrium Appoints James Halle as Chief Commercial Officer
Key appointment brings extensive software commercial experience to drive global growth
